SYNACT SynAct Pharma AB (publ)
SynAct Pharma AB (publ), a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. The company has a strategic alliance with Hipolabor Farmacêutica LTDA for resomelagon in the treatment of dengue in Brazil. SynAct Pharma AB (publ) was founded in 2012 and is headquartered in Lund, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About SynAct Pharma (STO: SYNACT)
›
SynAct Pharma (STO: SYNACT) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 8 employees.
The shares were at 13.00 SEK on 20 November 2026, down 40.2% over 52 weeks. Its 52-week range is 7.050 SEK to 24.50 SEK: the price is 46.9% below the high and 84.4% above the low.
Its market capitalisation is 727.98M SEK.
SynAct Pharma reports return on equity of -65.1% and an operating margin of 0.0%.
Its debt exceeds its cash by 3.17M SEK, a debt-to-equity ratio of 0.01. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 39.40 SEK is 203.1% above the current price.